Last update 13 Jun 2026

ANS-02

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ANS 02, ANS02
Target
EGFR
Action
antagonists
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)
Therapeutic Areas
NeoplasmsRespiratory Diseases
Active Indication
EGFR positive non-small cell lung cancerEGFR T790M Mutation Positive Non-Small Cell Lung CarcinomaEGFR-mutated non-small Cell Lung Cancer
Inactive Indication-
Originator Organization
Avistone Biotechnology Co., Ltd.Avistone Biotechnology Co., Ltd.
Active Organization
Avistone Biotechnology Co., Ltd.Avistone Biotechnology Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with ANS-02
NCT07538804
/ RecruitingPhase 1/2
A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS02 in Participants With EGFR Mutation-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
100 Clinical Results associated with ANS-02
Login to view more data
100 Translational Medicine associated with ANS-02
Login to view more data
100 Patents (Medical) associated with ANS-02
Login to view more data
100 Deals associated with ANS-02
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EGFR positive non-small cell lung cancerPhase 2
United States
Avistone Biotechnology Co., Ltd.Avistone Biotechnology Co., Ltd.
09 Jun 2026
EGFR positive non-small cell lung cancerPhase 2
China
Avistone Biotechnology Co., Ltd.Avistone Biotechnology Co., Ltd.
09 Jun 2026
EGFR T790M Mutation Positive Non-Small Cell Lung CarcinomaPhase 2
United States
Avistone Biotechnology Co., Ltd.Avistone Biotechnology Co., Ltd.
09 Jun 2026
EGFR T790M Mutation Positive Non-Small Cell Lung CarcinomaPhase 2
China
Avistone Biotechnology Co., Ltd.Avistone Biotechnology Co., Ltd.
09 Jun 2026
EGFR-mutated non-small Cell Lung CancerIND Approval
China
Avistone Biotechnology Co., Ltd.Avistone Biotechnology Co., Ltd.
10 Jun 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free